Advanced Technology Corporation
- Address
- lock Available on a paid plan
Virus Diseases and Infectious Disease Research
At Advanced Technology Corporation in Liege, Belgium, clinical trials in Virus Diseases focus on serious viral conditions such as HIV-1, HIV-1 infection, and respiratory syncytial virus infection. The research is aimed at evaluating new treatment options and better understanding how potential therapies perform in healthy participants and disease-related settings.
- Studies centered on HIV-1 and HIV-1 infection
- Research involving respiratory syncytial virus infection
- Testing new antiviral approaches for safety and effectiveness
These trials reflect the site’s role in advancing infectious disease research through early clinical evaluation of promising therapies.
Nervous System Diseases and Brain Disorder Research
The site also conducts studies in Nervous System Diseases, with attention to conditions such as narcolepsy and other brain-related disorders. The trials are designed to assess whether new therapies may be safe and well tolerated while helping researchers understand their potential to address unmet needs in neurology.
- Research in narcolepsy and related sleep-wake disorders
- Evaluation of novel treatments for brain diseases
- Early testing of candidate therapies in healthy volunteers
This area highlights the site’s interest in developing better options for people affected by complex neurological conditions.
Mental Disorders and Psychiatric Research
Clinical research in Mental Disorders includes studies related to post-traumatic stress disorder (PTSD), reflecting a focus on conditions that can strongly affect daily functioning and quality of life. The trials are intended to support the development of improved therapies and to explore how emerging treatments may help in psychiatry.
- Studies involving post-traumatic stress disorder (PTSD)
- Investigation of new approaches for psychiatric disorders
- Assessment of treatment safety and tolerability
Through this work, the site contributes to broader efforts to improve care for people living with challenging mental health conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Rest Therapeutics1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC5trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 307 other sites in Belgium
Therapeutic Area Benchmark — Belgium
Select a therapeutic area to compare against other sites in Belgium.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Belgium
Market Share
Country: Belgium
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Advanced Technology Corporation
lock Showing 1 of 9 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase I Multiple Ascending Dose Study of MK-3508 in Healthy Participants for the Treatment of Respiratory Syncytial Virus Infection | Merck Sharp & Dohme LLC | Phase I | Not Recruiting | Oct 2023 | Apr 2024 |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pitolisant | 1 | Unknown | 2023-09-26 | 2023-09-26 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.